<DOC>
	<DOCNO>NCT00005852</DOCNO>
	<brief_summary>RATIONALE : Bone marrow donor may able treat patient severe aplastic anemia patient whose body reject previous bone marrow transplantation . PURPOSE : Phase II trial study effectiveness bone marrow transplantation treat patient severe aplastic anemia whose body reject previous bone marrow transplant .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Severe Aplastic Anemia Rejection Previous Bone Marrow Transplant</brief_title>
	<detailed_description>OBJECTIVES : I . Determine graft failure rate overall survival patient severe aplastic anemia receive allogeneic bone marrow transplant . II . Determine efficacy high dose cyclophosphamide antithymocyte globulin condition regimen second bone marrow transplant patient reject first graft . III . Determine efficacy methylprednisolone anti-CD3 monoclonal antibody condition regimen second bone marrow transplant patient reject first graft poor candidate cyclophosphamide antithymocyte globulin . OUTLINE : Patients graft failure follow organ function performance status assign arm I : Performance status : Karnofsky 60-100 % Pulmonary : FEV1 DLCO least 50 % Cardiac : Left ventricular ejection fraction least 45 % Hepatic : None mild venoocclusive disease Patients graft failure follow organ function performance status assign arm II : Performance status : Karnofsky 20-50 % Pulmonary : FEV1 DLCO le 50 % Cardiac : Left ventricular ejection fraction le 45 % Hepatic : Moderate severe venoocclusive disease Patients aplastic anemia assign arm I . Arm I : Patients receive cyclophosphamide IV 1 hour day -5 -2 , antithymocyte globulin IV 8 hour day -5 -3 , bone marrow transplant day 0 . Arm II : Patients receive methylprednisolone IV twice day day -5 62 ; monoclonal antibody OKT3 IV day -1 24 ; bone marrow transplant day 0 ; oral cyclosporine twice day start day 20 ; filgrastim ( G-CSF ) subcutaneously day start day -5 blood count recover . Patients follow week 3 month monthly one year . PROJECTED ACCRUAL : A total 40 patient ( 20 aplastic anemia 20 graft failure ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Muromonab-CD3</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aplastic anemia Must relate donor genotypic 6 6 HLA A , B , DR match OR Bone marrow transplant failure Must relate donor least 5 6 HLA match OR Must unrelated donor least 5 6 HLA match PATIENT CHARACTERISTICS : Age : 15 55 Performance status : Aplastic anemia patient : Karnofsky 80100 % Graft failure patient : Karnofsky 20100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Aplastic anemia patient : Bilirubin great 2.0 mg/dL SGOT/SGPT great 3 time normal PT/PTT normal ( except aplastic anemia secondary viral hepatitis ) Graft failure patient : Mild severe venoocclusive disease allow Renal : Aplastic anemia patient : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : Aplastic anemia patient : Left ventricular ejection fraction least 45 % MUGA echocardiography No myocardial infarction within past 6 month No uncontrolled arrhythmia Pulmonary : Aplastic anemia patient : FEV1 DLCO least 50 % predict Other : Aplastic anemia patient : No uncontrolled diabetes mellitus thyroid disease No active serious infection HIV negative Not pregnant nursing Negative pregnancy test No psychosocial problem would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>graft versus host disease</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>